CN102552247B - Composition of vitamin C and preparation method thereof - Google Patents
Composition of vitamin C and preparation method thereof Download PDFInfo
- Publication number
- CN102552247B CN102552247B CN201210057860.XA CN201210057860A CN102552247B CN 102552247 B CN102552247 B CN 102552247B CN 201210057860 A CN201210057860 A CN 201210057860A CN 102552247 B CN102552247 B CN 102552247B
- Authority
- CN
- China
- Prior art keywords
- vitamin
- composition
- granule
- sodium
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title claims abstract description 102
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 title claims abstract description 51
- 229930003268 Vitamin C Natural products 0.000 title claims abstract description 51
- 239000011718 vitamin C Substances 0.000 title claims abstract description 51
- 235000019154 vitamin C Nutrition 0.000 title claims abstract description 51
- 239000000203 mixture Substances 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- 239000011248 coating agent Substances 0.000 claims abstract description 14
- 238000000576 coating method Methods 0.000 claims abstract description 14
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims abstract description 13
- 229960002079 calcium pantothenate Drugs 0.000 claims abstract description 13
- 235000019640 taste Nutrition 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims description 36
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000002131 composite material Substances 0.000 claims description 11
- 229920003023 plastic Polymers 0.000 claims description 11
- 239000004033 plastic Substances 0.000 claims description 11
- 239000007921 spray Substances 0.000 claims description 9
- 239000011230 binding agent Substances 0.000 claims description 7
- 239000002245 particle Substances 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 230000000873 masking effect Effects 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- 239000004925 Acrylic resin Substances 0.000 claims description 3
- 229920000178 Acrylic resin Polymers 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 3
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 3
- 239000008116 calcium stearate Substances 0.000 claims description 3
- 235000013539 calcium stearate Nutrition 0.000 claims description 3
- 229940078456 calcium stearate Drugs 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 238000007599 discharging Methods 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 238000000889 atomisation Methods 0.000 claims 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims 1
- 244000248349 Citrus limon Species 0.000 claims 1
- 235000005979 Citrus limon Nutrition 0.000 claims 1
- 229920003114 HPC-L Polymers 0.000 claims 1
- 239000008118 PEG 6000 Substances 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 229960000935 dehydrated alcohol Drugs 0.000 claims 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000007602 hot air drying Methods 0.000 claims 1
- 229940085605 saccharin sodium Drugs 0.000 claims 1
- 235000010378 sodium ascorbate Nutrition 0.000 claims 1
- 229960005055 sodium ascorbate Drugs 0.000 claims 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims 1
- -1 unit type MP-01 Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 7
- 239000000796 flavoring agent Substances 0.000 abstract description 7
- 239000000463 material Substances 0.000 abstract description 7
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 239000000945 filler Substances 0.000 abstract description 5
- 239000004014 plasticizer Substances 0.000 abstract description 5
- 235000013599 spices Nutrition 0.000 abstract description 5
- 235000013355 food flavoring agent Nutrition 0.000 abstract description 4
- 230000006870 function Effects 0.000 abstract description 4
- 239000000314 lubricant Substances 0.000 abstract description 4
- 239000000546 pharmaceutical excipient Substances 0.000 abstract description 4
- 229940124531 pharmaceutical excipient Drugs 0.000 abstract description 4
- 239000008298 dragée Substances 0.000 abstract description 3
- 230000036541 health Effects 0.000 abstract description 3
- 239000007940 sugar coated tablet Substances 0.000 abstract description 3
- 239000000375 suspending agent Substances 0.000 abstract description 3
- 230000009747 swallowing Effects 0.000 abstract description 3
- 230000007012 clinical effect Effects 0.000 abstract description 2
- 239000000576 food coloring agent Substances 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 239000000853 adhesive Substances 0.000 abstract 1
- 230000001070 adhesive effect Effects 0.000 abstract 1
- 230000009977 dual effect Effects 0.000 abstract 1
- 239000011734 sodium Substances 0.000 description 9
- 238000004806 packaging method and process Methods 0.000 description 8
- 229910052708 sodium Inorganic materials 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 6
- 208000012641 Pigmentation disease Diseases 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000007771 core particle Substances 0.000 description 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010014970 Ephelides Diseases 0.000 description 3
- 208000003351 Melanosis Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 206010042496 Sunburn Diseases 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 206010013911 Dysgeusia Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010047623 Vitamin C deficiency Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000007931 coated granule Substances 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical group CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960002900 methylcellulose Drugs 0.000 description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 208000010233 scurvy Diseases 0.000 description 2
- 235000019614 sour taste Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- UJMBCXLDXJUMFB-GLCFPVLVSA-K tartrazine Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-GLCFPVLVSA-K 0.000 description 2
- 229960000943 tartrazine Drugs 0.000 description 2
- 235000012756 tartrazine Nutrition 0.000 description 2
- 239000004149 tartrazine Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000006770 Ascorbic Acid Deficiency Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- 229940068682 chewable tablet Drugs 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002737 fructose Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000004518 granules dosage form Substances 0.000 description 1
- 208000011759 gum bleeding Diseases 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000001040 synthetic pigment Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 210000001779 taste bud Anatomy 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 206010044697 tropical sprue Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了一种维生素C的组合物,所述组合物由活性成分与药用辅料按下列重量百分配比组成:(1)活性成分:维生素C5~30、维生素C钠3.25~19.25%、泛酸钙0.2~0.8%;(2)药用辅料:润滑剂0.05~0.45%、混悬剂1~9%、填充剂30~80%、粘合剂0.5~4.5%、增塑剂0.05~2.45%、矫味剂0.2~0.8%、香料0.2~0.8%、食用色素0.2~0.8%、包衣材料0.05~5.45%。本发明的维生素C组合物口感好,不需水或仅需少量水服用,携带使用方便,稳定性好,吸收起效迅速,提高了服用依从性,兼具治疗及保健双重作用,特别适用于小儿或高龄以及一些吞咽难患者使用。本发明的维生素C的组合物无论从外观以及含量上,均优于维生素C糖衣片。本发明的维生素C的组合物稳定性有较大改善。本发明制备工艺合理,操作简便,宜于工业化生产。有较好的临床效果和较大的应用价值。The invention provides a composition of vitamin C, which is composed of active ingredients and pharmaceutical excipients according to the following weight ratio: (1) active ingredients: vitamin C 5-30%, vitamin C sodium 3.25-19.25%, Calcium pantothenate 0.2-0.8%; (2) Pharmaceutical excipients: lubricant 0.05-0.45%, suspending agent 1-9%, filler 30-80%, adhesive 0.5-4.5%, plasticizer 0.05-2.45% %, flavoring agent 0.2-0.8%, spice 0.2-0.8%, food coloring 0.2-0.8%, coating material 0.05-5.45%. The vitamin C composition of the present invention has a good taste, does not need water or only needs a small amount of water to take, is convenient to carry and use, has good stability, absorbs and takes effect quickly, improves the compliance of taking, and has dual functions of treatment and health care, and is especially suitable for Children or the elderly and some patients with difficulty swallowing. The vitamin C composition of the present invention is superior to the vitamin C sugar-coated tablet in terms of appearance and content. The stability of the vitamin C composition of the present invention is greatly improved. The preparation process of the invention is reasonable, the operation is simple and convenient, and it is suitable for industrial production. It has good clinical effect and great application value.
Description
技术领域 technical field
本发明涉及药物制剂。具体涉及一种维生素C的组合物及制备方法。The present invention relates to pharmaceutical preparations. Specifically relates to a vitamin C composition and a preparation method.
背景技术 Background technique
维生素C与脱氢维生素C在体内形成一个可逆的氧化还原系统,该系统在生物氧化及还原作用和细胞呼吸中起着重要的作用。维生素C参与氨基酸代谢、神经递质的合成,以及胶原蛋白和组织细胞间质的合成,对人体健康至关重要。维生素C的主要生理功能:促进骨胶原的生物合成,有利于组织创伤口的更快愈合,促进氨基酸中酪氨酸和色氨酸的代谢,延长肌体寿命,改善铁、钙和叶酸的利用,改善脂肪和类脂特别是胆固醇的代谢,预防心血管病,促进牙齿和骨骼的生长,防止牙床出血,增强肌体对外界环境的抗应激能力和免疫力。并且维生素C还可阻断黑色素形成,能增强皮肤弹性,预防色斑,具有美容作用等。维生素C钠已用作营养补充剂和抗氧化剂,具有无酸味,易溶于水优点,并增加了维生素C的稳定性。目前,维生素C制剂有普通片、咀嚼片、泡腾片、分散片、口含片、注射液等各种剂型。但是,都不同程度地存在易变色、易降解、稳定性差、携带和使用不便以及生产工艺复杂(咀嚼片、泡腾片、分散片、注射液)等缺陷。另外,维生素C的酸涩不良味觉,当与味蕾接触时,就会把感受到的不良刺激的信息传送至大脑皮质中枢,产生不良味觉,导致服用的顺应性差,影响了维生素C的临床使用。因此,人们对改善维生素C制剂的服用性和便携性的需求越来越高。尤其是对于小儿或者高龄患者以及一些吞咽困难的患者来说,可以直接吞服的颗粒剂型产品更加容易被接受。同时掩盖药物不良味道,改善患者依从性,一直是医药界努力的目标。然而,本发明人发现泛酸钙与维生素C组合产生了意想不到的效果。泛酸钙对于人体养颜和改善疲劳等方面有很多作用。另外临床上也用于泛酸钙缺乏(如吸收不良综合症,热带口炎性腹泻、乳糜泄、局限性肠炎)的预防和治疗,同时能缓和斑点雀斑、晒伤、皮肤炎症的色素沉着等。当维生素C与泛酸钙组合,不仅能改善维生素C制剂的缺陷,还增加了用途。因此,研究维生素C组合物制剂是关注的问题。Vitamin C and dehydrovitamin C form a reversible redox system in the body, which plays an important role in biological oxidation and reduction and cellular respiration. Vitamin C participates in the metabolism of amino acids, the synthesis of neurotransmitters, and the synthesis of collagen and tissue interstitium, which is very important to human health. The main physiological functions of vitamin C: promote the biosynthesis of collagen, facilitate the faster healing of tissue wounds, promote the metabolism of tyrosine and tryptophan in amino acids, prolong the life of the body, improve the utilization of iron, calcium and folic acid, Improve the metabolism of fats and lipids, especially cholesterol, prevent cardiovascular diseases, promote the growth of teeth and bones, prevent gum bleeding, and enhance the body's ability to resist stress and immunity to the external environment. And vitamin C can also block the formation of melanin, enhance skin elasticity, prevent pigmentation, and have cosmetic effects. Sodium vitamin C has been used as a nutritional supplement and antioxidant, and has the advantages of no sour taste, easy solubility in water, and increased stability of vitamin C. At present, vitamin C preparations have various dosage forms such as ordinary tablets, chewable tablets, effervescent tablets, dispersible tablets, buccal tablets, and injections. But all have defects such as easy discoloration, easy degradation, poor stability, inconvenience to carry and use and complex production process (chewable tablet, effervescent tablet, dispersible tablet, injection) to varying degrees. In addition, the sour and astringent taste of vitamin C, when in contact with the taste buds, will transmit the information of the bad stimulus to the cerebral cortex center, resulting in bad taste, resulting in poor compliance of taking, which affects the clinical use of vitamin C. Therefore, people have higher and higher demands for improving the taking and portability of vitamin C preparations. Especially for children or elderly patients and some patients who have difficulty swallowing, granule products that can be swallowed directly are more acceptable. At the same time, it has been the goal of the pharmaceutical industry to cover up the bad taste of drugs and improve patient compliance. However, the present inventors found that the combination of calcium pantothenate and vitamin C produced an unexpected effect. Calcium pantothenate has many effects on human body beauty and fatigue improvement. In addition, it is also clinically used for the prevention and treatment of calcium pantothenate deficiency (such as malabsorption syndrome, tropical sprue, celiac disease, Crohn's disease), and at the same time, it can alleviate pigmentation of spots, freckles, sunburn, and skin inflammation. When vitamin C is combined with calcium pantothenate, it can not only improve the defects of vitamin C preparations, but also increase the uses. Therefore, research into vitamin C composition formulations is a matter of interest.
发明内容 Contents of the invention
本发明要解决的技术问题在于克服上述不足之处,研究设计携带服用方便、吸收起效迅速、稳定性好,以及便于携带的维生素C组合物。The technical problem to be solved by the present invention is to overcome the above disadvantages, research and design a vitamin C composition that is easy to carry and take, fast to absorb and take effect, good in stability, and easy to carry.
本发明一种维生素C的组合物,所述组合物由活性成分与药用辅料按下列重量百分配比组成:A vitamin C composition according to the present invention, said composition is composed of active ingredients and pharmaceutical excipients according to the following weight ratio:
(1)活性成分:(1) Active ingredients:
维生素C 5~30%Vitamin C 5~30%
维生素C钠 3.25~19.25%Sodium vitamin C 3.25~19.25%
泛酸钙 0.2~0.8%Calcium pantothenate 0.2~0.8%
;;
(2)药用辅料(2) Pharmaceutical excipients
优选的,本发明一种维生素C组合物,所述组合物由下列重量配比的成分组成:2000g/1000袋Preferably, a vitamin C composition of the present invention, said composition is composed of the following components by weight ratio: 2000g/1000 bags
本发明所述组合物为颗粒剂,1-3g(每袋)。The composition of the present invention is granule, 1-3g (per bag).
本发明所述组合物中各组分的功能如下:The function of each component in the composition of the present invention is as follows:
所述活性成分包括:维生素C、维生素C钠和泛酸钙。其中维生素C钠兼具抗氧剂及维生素C的作用;泛酸钙对于人体养颜和改善疲劳等方面有很多作用,同时能缓和斑点雀斑、晒伤、皮肤炎症的色素沉着等。The active ingredients include: vitamin C, sodium vitamin C and calcium pantothenate. Among them, sodium vitamin C has the functions of antioxidant and vitamin C; calcium pantothenate has many effects on human body beauty and fatigue improvement, and can relieve pigmentation of spots, freckles, sunburn, and skin inflammation.
所述药用辅料包括润滑剂、混悬剂、填充剂、粘合剂、增塑剂、The pharmaceutical auxiliary materials include lubricants, suspending agents, fillers, binders, plasticizers,
矫味剂、香料、食用色素、包衣材料。Flavoring agents, spices, food coloring, coating materials.
润滑剂:包括但不限于硬脂酸镁、硬脂酸钙、单硬脂酸甘油酯、聚乙二醇、氢化植物油、十二烷基硫酸钠、十二烷基硫酸镁、滑石粉等,可单独使用,也可组合使用。可以改善原料流动性,消除静电吸附,有利于粉碎及掩味包衣的顺利进行。Lubricants: including but not limited to magnesium stearate, calcium stearate, glyceryl monostearate, polyethylene glycol, hydrogenated vegetable oil, sodium lauryl sulfate, magnesium lauryl sulfate, talc, etc. Can be used alone or in combination. It can improve the fluidity of raw materials, eliminate electrostatic adsorption, and facilitate the smooth progress of crushing and taste-masking coating.
掩味颗粒:由包衣型高分子材料包衣掩味而成。Taste-masking granules: taste-masking coated with coated polymer materials.
包衣材料:包括但不限于丙烯酸树脂L-100、乙基纤维素、羟丙甲纤维素、聚乙烯吡咯烷酮、甲基纤维素、明胶、阿拉伯胶、玉米朊、海藻酸钠、壳聚糖等,可单独使用,也可组合使用。配制为水或乙醇溶液包衣,达掩味目的。Coating materials: including but not limited to acrylic resin L-100, ethyl cellulose, hypromellose, polyvinylpyrrolidone, methyl cellulose, gelatin, gum arabic, zein, sodium alginate, chitosan, etc. , can be used alone or in combination. Prepared as water or ethanol solution coating, to achieve the purpose of taste masking.
矫味颗粒:由混悬剂、填充剂与上述颗粒用粘合剂溶液(含矫味剂、增塑剂、香料、色素)经流化床工艺制粒而成。Flavor granules: Suspensions, fillers and the above granules are granulated with a binder solution (including flavors, plasticizers, spices, and pigments) through fluidized bed technology.
混悬剂:包括但不限于微晶纤维素-羧甲基淀粉钠(RC-591)、羧甲基纤维素钠(CMC钠)、聚乙烯吡咯烷酮(PVP)、黄胶原、羧甲基淀粉钠(CMS钠)、羟丙基甲基纤维素(HPMC)等,可单独使用,也可组合使用。在颗粒中起混悬稳定剂的作用。Suspension: including but not limited to microcrystalline cellulose-sodium carboxymethyl starch (RC-591), sodium carboxymethyl cellulose (sodium CMC), polyvinylpyrrolidone (PVP), xanthan collagen, sodium carboxymethyl starch (CMS sodium), hydroxypropyl methylcellulose (HPMC), etc., can be used alone or in combination. Acts as a suspension stabilizer in the granules.
填充剂:包括但不限于甘露醇、山梨醇、麦芽糖、微晶纤维素、葡萄糖、蔗糖、乳糖、糊精等,可以单独使用,也可以组合使用。Fillers: including but not limited to mannitol, sorbitol, maltose, microcrystalline cellulose, glucose, sucrose, lactose, dextrin, etc., which can be used alone or in combination.
粘合剂:包括但不限于羟丙基纤维素(HPC-L)、HPMC、PVP、淀粉、糊精、甲基纤维素、海藻酸及海藻酸盐等,可单独使用,也可组合使用。根据工艺需要配制为水或乙醇溶液作为造粒的粘合剂。Binder: including but not limited to hydroxypropyl cellulose (HPC-L), HPMC, PVP, starch, dextrin, methylcellulose, alginic acid and alginate, etc., which can be used alone or in combination. According to the needs of the process, it can be prepared as a water or ethanol solution as a binder for granulation.
矫味剂:包括但不限于糖精钠、阿斯帕坦、乳糖、果糖、蔗糖、甜菊素、甘露醇、木糖醇等,可单独使用,也可组合使用。在掩味基础上起到矫味作用。Flavoring agents: including but not limited to sodium saccharin, aspartame, lactose, fructose, sucrose, stevia, mannitol, xylitol, etc., which can be used alone or in combination. On the basis of taste masking, it plays a role of flavor correction.
增塑剂:包括但不限于聚乙二醇6000(PEG6000)、聚乙二醇4000(PEG4000)、柠檬酸三乙酯、鲸蜡醇等,可单独使用,也可组合使用。起改善颗粒外观作用。Plasticizers: including but not limited to polyethylene glycol 6000 (PEG6000), polyethylene glycol 4000 (PEG4000), triethyl citrate, cetyl alcohol, etc., which can be used alone or in combination. Play a role in improving the appearance of particles.
香料:包括但不限于香精、薄荷、香兰素、乙基香兰素等,可单独使用,也可组合使用。起到改善嗅觉更易于使人接受的作用。Spices: including but not limited to essence, mint, vanillin, ethyl vanillin, etc., which can be used alone or in combination. Play a role in improving the sense of smell and making it easier for people to accept.
色素:为自然或人工合成的在制药工业及食品工业中可以接受的色素,包括但不限于柠檬黄、日落黄、胡萝卜色素、姜黄色素等,可单独使用,也可组合使用起改善颗粒外观作用。可以使颗粒外观更漂亮,更易于使人接受。Pigments: natural or synthetic pigments acceptable in the pharmaceutical and food industries, including but not limited to tartrazine, sunset yellow, carotene, curcumin, etc., which can be used alone or in combination to improve the appearance of granules . It can make the appearance of particles more beautiful and more acceptable.
本发明的另一目的是提供了一种维生素C的组合物制备方法。Another object of the present invention is to provide a method for preparing a vitamin C composition.
本发明所述方法包括核心颗粒制备、掩味颗粒制备与矫味颗粒制备,具体包括下列步骤:The method of the present invention comprises preparation of core granules, preparation of taste-masking granules and preparation of flavor-correcting granules, specifically comprising the following steps:
(一)核心颗粒制备:(1) Preparation of core particles:
将维生素C、维生素C钠、泛酸钙与润滑剂充分混合均匀,然后将混合物粉碎至粒径为25-50um,制成核心颗粒;Fully mix vitamin C, vitamin C sodium, calcium pantothenate and lubricant, and then crush the mixture to a particle size of 25-50um to make core particles;
(二)掩味颗粒制备:(2) Preparation of taste-masking granules:
将(一)的核心颗粒置于流化床包衣机中,用高分子包衣材料配制的无水乙醇溶液(浓度5-10%)连续喷雾包衣,包衣后颗粒过80目筛,制成掩味颗粒;设定喷量10g/min,喷雾压力0.5MPa,进风量1m3/min,进风温度80℃;包衣后50℃干燥15min。The core granules of (1) are placed in a fluidized bed coating machine, continuously sprayed with an anhydrous ethanol solution (concentration 5-10%) prepared by a polymer coating material, and the coated granules are passed through an 80-mesh sieve. Make taste-masking granules; set the spray volume at 10g/min, the spray pressure at 0.5MPa, the air intake volume at 1m 3 /min, and the air intake temperature at 80°C; and dry at 50°C for 15min after coating.
(三)矫味颗粒制备(3) Preparation of flavoring granules
将(二)的掩味颗粒与混悬剂、填充剂混合后置于流化床;另用水或乙醇溶解的粘合剂、增塑剂、矫味剂、香料和色素,制成3-9%的溶液,连续喷液,喷完后于40-50℃热风干燥,出料,过20目筛,即得矫味颗粒。Mix the taste-masking granules of (2) with suspending agents and fillers and place them in a fluidized bed; in addition, dissolve binders, plasticizers, flavoring agents, spices and pigments in water or ethanol to make 3-9 % solution, continuous spraying, drying in hot air at 40-50°C after spraying, discharging, passing through a 20-mesh sieve to obtain flavoring granules.
根据服用要求的规格采用铝塑复合袋包装即可(每袋的重量1-3g)。According to the specifications required for taking, it can be packed in aluminum-plastic composite bags (the weight of each bag is 1-3g).
本发明将维生素C、维生素C钠与泛酸钙的组合物制成颗粒剂,并且,分步制成核心颗粒、掩味颗粒、矫味颗粒,有很好的效果。本发明首先将维生素C、维生素C钠制成核心颗粒可防止维生素C受氧气、水分而影响稳定性,显著提高了维生素C组合物的稳定性。进一步将高分子包衣材料包裹在有不良味道的药物颗粒表面,从而减少了药物在口腔中溶出,达到掩味目的。最后制成矫味颗粒,使本发明的颗粒剂味觉、口感佳,剂量准确。另外,本发明颗粒剂便于携带和服用,不需水或仅需少量水,无需咀嚼,借助吞咽动力即可进入胃,组合物中的维生素C、维生素C钠及泛酸钙在胃液中形成高度分散的细颗粒,提高了生物利用度。由于本发明组合物口感佳,吸收快,有利于患者服用,增加依从性。同时还兼具治疗泛酸钙缺乏症以及缓和斑点、雀斑、晒伤、皮肤炎症的色素沉着等美容保健作用。目前尚未见本发明组合物及颗粒剂型的相关报道。In the present invention, the composition of vitamin C, vitamin C sodium and calcium pantothenate is made into granules, and core granules, taste-masking granules and flavor-correcting granules are prepared step by step, which has good effect. In the present invention, vitamin C and vitamin C sodium are first made into core particles, which can prevent the stability of vitamin C from being affected by oxygen and moisture, and significantly improve the stability of the vitamin C composition. The polymer coating material is further coated on the surface of the bad-tasting drug particles, thereby reducing the dissolution of the drug in the oral cavity and achieving the purpose of taste masking. Finally, flavor-correcting granules are made, so that the granules of the present invention have good taste and mouthfeel and accurate dosage. In addition, the granules of the present invention are easy to carry and take, do not need water or only need a small amount of water, do not need to chew, and can enter the stomach with the help of swallowing power, and the vitamin C, sodium vitamin C and calcium pantothenate in the composition form a highly dispersed The fine particles improve bioavailability. Because the composition of the invention has good taste and fast absorption, it is beneficial for patients to take and increase compliance. At the same time, it also has the functions of beauty and health care such as treating calcium pantothenate deficiency and relieving pigmentation of spots, freckles, sunburn, and skin inflammation. There is no relevant report on the composition and granule dosage form of the present invention.
本发明维生素C组合物能用于预防和治疗维生素C缺乏引起的疾病(如坏血病、牙龈出血、鼻出血),也可用于增强机体抵抗力,预防心、脑血管病,对创伤愈合期、机体疲劳时、妊娠、授乳期、病中病后恢复期等体力低下以及习惯性流产,不孕症与皮肤色素沉着等的辅助治疗。本发明为颗粒剂,克服了维生素C现有剂型的缺陷。本发明制备工艺合理,操作简便,宜于工业化生产。有较好的临床效果和较大的应用价值。The vitamin C composition of the present invention can be used to prevent and treat diseases caused by vitamin C deficiency (such as scurvy, bleeding gums, nosebleeds), and can also be used to enhance the body's resistance, prevent cardiovascular and cerebrovascular diseases, and treat wounds during the healing period. , Physical fatigue, pregnancy, breast-feeding period, recovery period after illness and other low physical strength and habitual abortion, infertility and skin pigmentation, etc. adjuvant treatment. The invention is a granule, which overcomes the defects of the existing formulations of vitamin C. The preparation process of the invention is reasonable, the operation is simple and convenient, and it is suitable for industrial production. It has good clinical effect and great application value.
具体实施方式 Detailed ways
为了更好地说明本发明所述维生素C组合物及制备方法,结合实施例作进一步说明。In order to better illustrate the vitamin C composition and preparation method of the present invention, further description will be made in conjunction with examples.
实施例1Example 1
制备方法:Preparation:
1)将维生素C、维生素C-Na、硬脂酸钙充分混和均匀,并粉碎至粒径25-50um,得到核心颗粒。1) Thoroughly mix vitamin C, vitamin C-Na, and calcium stearate evenly, and grind to a particle size of 25-50um to obtain core granules.
2)将1)的核心颗粒置于流化床包衣机(设备型号SFP-01)中,将丙烯酸树脂L100与无水乙醇316.25g配制为8%乙醇溶液作为浆液,连续喷雾包衣;设定喷量10g/min,喷雾压力0.5MPa,进风量1m3/min,进风温度80℃;包衣后50℃干燥15min。2) Put the core particles of 1) in a fluidized bed coating machine (equipment model SFP-01), prepare an 8% ethanol solution as a slurry with acrylic resin L100 and absolute ethanol 316.25 g, and spray coating continuously; The fixed spray volume is 10g/min, the spray pressure is 0.5MPa, the air intake volume is 1m 3 /min, and the air intake temperature is 80°C; after coating, it is dried at 50°C for 15min.
3)将2)包衣后颗粒过80目筛得到掩味颗粒;3) passing 2) the coated granules through an 80-mesh sieve to obtain taste-masked granules;
4)将3)颗粒与微晶纤维素、微晶纤维素-羧甲基纤维素钠混合后置于流化床(设备型号MP-01),用水(具体量?447.5g)溶解HPC-L、PEG6000、糖精钠、香精和柠檬黄,配制成5%HPC溶液作为粘合剂,设定喷液量为10g/min,喷雾压力0.5MPa,进风量1m3/min,进风温度80℃,用顶喷的方式喷液,喷完后于40-50℃热风干燥,出料,过20目筛,即得矫味颗粒;4) Mix 3) granules with microcrystalline cellulose, microcrystalline cellulose-carboxymethyl cellulose sodium and place them in a fluidized bed (equipment model MP-01), and dissolve HPC-L with water (specific amount? 447.5g) , PEG6000, sodium saccharin, essence and tartrazine, prepared into 5% HPC solution as a binder, set the spray volume to 10g/min, spray pressure to 0.5MPa, air intake volume to 1m 3 /min, air intake temperature to 80°C, Spray the liquid in the way of top spray, dry it with hot air at 40-50°C after spraying, discharge the material, and pass through a 20-mesh sieve to obtain flavored granules;
5)包装:4)的矫味颗粒用铝塑复合袋包装为1g/袋。5) Packing: 4) the flavoring granules are packed in an aluminum-plastic composite bag at 1g/bag.
实施例2Example 2
制备方法:Preparation:
按照实施例1所述制备工艺操作,包装规格铝塑复合袋装2g/袋。According to the preparation process described in Example 1, the packaging specification is 2g/bag in an aluminum-plastic composite bag.
实施例3Example 3
制备方法:Preparation:
按照实施例1所述制备工艺操作,包装规格铝塑复合袋装3g/袋。According to the preparation process described in Example 1, the packaging specification is 3g/bag in an aluminum-plastic composite bag.
实施例4Example 4
制备方法:Preparation:
按照实施例1所述制备工艺操作,包装规格铝塑复合袋装1g/袋。According to the preparation process described in Example 1, the packaging specification is 1g/bag in an aluminum-plastic composite bag.
实施例5Example 5
制备方法:Preparation:
按照实施例1所述制备工艺操作,包装规格铝塑复合袋装1g/袋。According to the preparation process described in Example 1, the packaging specification is 1g/bag in an aluminum-plastic composite bag.
实施例6Example 6
制备方法:Preparation:
按照实施例1所述制备工艺操作,包装规格铝塑复合袋装1g/袋。According to the preparation process described in Example 1, the packaging specification is 1g/bag in an aluminum-plastic composite bag.
实施例7Example 7
制备方法:Preparation:
按照实施例1所述制备工艺操作,包装规格铝塑复合袋装1g/袋。According to the preparation process described in Example 1, the packaging specification is 1g/bag in an aluminum-plastic composite bag.
实施例8Example 8
制备方法:Preparation:
按照实施例1所述制备工艺操作,包装规格铝塑复合袋装1g/袋。According to the preparation process described in Example 1, the packaging specification is 1g/bag in an aluminum-plastic composite bag.
实施例9Example 9
制备方法:Preparation:
按照实施例1所述制备工艺操作,包装规格铝塑复合袋装1g/袋。According to the preparation process described in Example 1, the packaging specification is 1g/bag in an aluminum-plastic composite bag.
实施例10 稳定性考察Example 10 Stability investigation
按照实施例1-9制得的维生素C的组合物颗粒剂,置于60℃/10天条件下考察口味、外观性状、维生素C含量等指标,结果表明质量稳定(见下表一),并且明显优于维生素C糖衣片(由常州市第四制药厂有限公司生产,批号为20100701、20100702、20110301)(见下表二):The vitamin C composition granules prepared according to Examples 1-9 were placed at 60° C./10 days to investigate indicators such as taste, appearance, vitamin C content, and the results showed that the quality was stable (see Table 1 below), and Obviously better than vitamin C sugar-coated tablets (produced by Changzhou Fourth Pharmaceutical Factory Co., Ltd., batch numbers are 20100701, 20100702, 20110301) (see Table 2 below):
表一Table I
表二Table II
表一和表二显著地表明,本发明的维生素C的组合物无论从外观以及含量上,均优于维生素C糖衣片。本发明的维生素C的组合物稳定性有较大的改善。Table 1 and Table 2 clearly show that the vitamin C composition of the present invention is superior to vitamin C sugar-coated tablets in terms of appearance and content. The stability of the vitamin C composition of the present invention is greatly improved.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210057860.XA CN102552247B (en) | 2012-03-07 | 2012-03-07 | Composition of vitamin C and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210057860.XA CN102552247B (en) | 2012-03-07 | 2012-03-07 | Composition of vitamin C and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102552247A CN102552247A (en) | 2012-07-11 |
CN102552247B true CN102552247B (en) | 2014-05-28 |
Family
ID=46399712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210057860.XA Active CN102552247B (en) | 2012-03-07 | 2012-03-07 | Composition of vitamin C and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102552247B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103099787B (en) * | 2013-02-19 | 2014-06-25 | 青岛正大海尔制药有限公司 | Vitamin C dry suspension |
KR101882820B1 (en) * | 2015-12-30 | 2018-07-30 | 주식회사 삼양바이오팜 | Mucoadhesive pharmaceutical composition and preparation method thereof |
CN110115384A (en) * | 2018-02-06 | 2019-08-13 | 浙江新维士生物科技有限公司 | Vitamin C composition and the method and vitamin C coated slow release piece for preparing vitamin C coated slow release piece |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1593411A (en) * | 2004-01-15 | 2005-03-16 | 范敏华 | Speckle removing pharmaceutical composition |
CN1327838C (en) * | 2004-07-08 | 2007-07-25 | 北京科信必成医药科技发展有限公司 | Vitamin C oral disintegration tablet and its preparing method |
CN1785179A (en) * | 2004-12-10 | 2006-06-14 | 北京昭衍博纳新药研究有限公司 | Compounding chewable vitamin tablets and its prepn. method |
CN100438778C (en) * | 2005-01-20 | 2008-12-03 | 北京科信必成医药科技发展有限公司 | Health food with hypoxia preventing and anti-fatigue function and preparation technique thereof |
-
2012
- 2012-03-07 CN CN201210057860.XA patent/CN102552247B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN102552247A (en) | 2012-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5637624B2 (en) | Disintegrating particle composition and fast disintegrating compression molding using the same | |
JP6064156B2 (en) | Deep body temperature raising agent | |
KR20200065009A (en) | Rapid onset and prolonged action Plant-based and synthetic cannabinoid formulations | |
JP5956475B2 (en) | Orally disintegrating tablets containing bitter mask granules | |
JP2008537678A (en) | Lignan-containing composition | |
WO2008034316A1 (en) | Compound preparation capable of reducing oxidative stress rapidly and the preparative method thereof | |
JP2016174616A (en) | Disintegrable composition, and easily disintegrable compression molding | |
JP2006124327A (en) | Abnormal protein removal composition | |
JP5633028B2 (en) | Sympathetic nerve activator | |
US20220249505A1 (en) | Appetite suppressant compositions and methods thereof | |
CN102552247B (en) | Composition of vitamin C and preparation method thereof | |
JP2004242509A (en) | Foods containing coenzyme Q10 and amino acids | |
CN109010361B (en) | Calcichew D3 preparation and preparation method thereof | |
JP2011026311A (en) | Method for producing tablet quickly disintegrating in oral cavity | |
CN112426408B (en) | Melatonin composition and preparation process thereof | |
CN106387895A (en) | Cerasus humilis leaf chewable tablet and preparation method thereof | |
JP6104038B2 (en) | Composite composition of crystalline cellulose | |
CN101543298A (en) | Rutin chewing agent and method for preparing same | |
CN105963330B (en) | Miracle fruit preparation and its application | |
CN1961859B (en) | Novel formulation of Tizanidine and derivative thereof and preparation method thereof | |
AU2015101120A4 (en) | Formulation for oral administration | |
US9308261B2 (en) | Compositions and methods for treating varicose veins | |
JP2023096840A (en) | Food composition for skin quality improvement | |
CN107223960A (en) | It is a kind of that there is composition of improvement prostate gland symptoms and preparation method thereof | |
TWI703989B (en) | Oral retention type disintegrating solid preparation, its manufacturing method, and powder composition used in the manufacturing method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20120711 Assignee: CHANGZHOU SIYAO PHARMACY Co.,Ltd. Assignor: CHANGZHOU SIYAO PHARM Co.,Ltd. Contract record no.: 2017320000019 Denomination of invention: Composition of vitamin C and preparation method thereof Granted publication date: 20140528 License type: Exclusive License Record date: 20170223 |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170522 Address after: 213018 No. 567 Wu Cheng Road, Changzhou, Jiangsu Patentee after: CHANGZHOU SIYAO PHARMACY Co.,Ltd. Address before: 213004 Jiangsu province Changzhou City Palace Road No. 168 Patentee before: CHANGZHOU SIYAO PHARM Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20250120 Address after: 213018 Wudao 567, Tianning District, Changzhou City, Jiangsu Province Patentee after: CHANGZHOU SIYAO PHARM Co.,Ltd. Country or region after: China Address before: 213018 No. 567 Zhongwu Avenue, Changzhou City, Jiangsu Province Patentee before: CHANGZHOU SIYAO PHARMACY Co.,Ltd. Country or region before: China |